Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study
Marwan Fakih, Kanwal Pratap Singh Raghav, David Chang, et al.
EClinicalMedicine (2023) Vol. 58, pp. 101917-101917
Open Access | Times Cited: 54

Showing 1-25 of 54 citing articles:

Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial
Feng Wang, Ying Jin, Min Wang, et al.
Nature Medicine (2024) Vol. 30, Iss. 4, pp. 1035-1043
Closed Access | Times Cited: 51
Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials
Hung‐Yang Kuo, Kabir A. Khan, Robert S. Kerbel
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 6, pp. 468-482
Closed Access | Times Cited: 29
Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study
Akihito Kawazoe, Rui‐Hua Xu, Pilar García‐Alfonso, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 24, pp. 2918-2927
Open Access | Times Cited: 26
Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial
Andrea J. Bullock, Benjamin L. Schlechter, Marwan Fakih, et al.
Nature Medicine (2024) Vol. 30, Iss. 9, pp. 2558-2567
Open Access | Times Cited: 24
Effect of radiotherapy exposure on fruquintinib plus sintilimab treatment in refractory microsatellite stable metastatic colorectal cancer: a prospective observation study
Mingxia Cheng, Min Jin, Shengli Yang, et al.
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 1, pp. e009415-e009415
Open Access | Times Cited: 3
Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort
Anwaar Saeed, Robin Park, Harsh B. Pathak, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 15
Multiomic molecular characterization of the response to combination immunotherapy in MSS/pMMR metastatic colorectal cancer
Shogo Takei, Yosuke Tanaka, Yi-Tzu Lin, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 2, pp. e008210-e008210
Open Access | Times Cited: 9
Regorafenib plus sintilimab as a salvage treatment for microsatellite stable metastatic colorectal cancer: a single-arm, open-label, phase II clinical trial
Rui Liu, Zhi Ji, Xia Wang, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 1
The Efficacy of Immune Checkpoint Inhibitors in Microsatellite Stable Colorectal Cancer: A Systematic Review
Deniz Can Güven, Gözde Kavgacı, Enes Erul, et al.
The Oncologist (2024) Vol. 29, Iss. 5, pp. e580-e600
Open Access | Times Cited: 7
An international phase II trial and immune profiling of SBRT and atezolizumab in advanced pretreated colorectal cancer
Antonin Lévy, Daphné Morel, Matthieu Texier, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 7
Molecular insights into clinical trials for immune checkpoint inhibitors in colorectal cancer: Unravelling challenges and future directions
Samantha Sharma, Naresh Singh, Anita Turk, et al.
World Journal of Gastroenterology (2024) Vol. 30, Iss. 13, pp. 1815-1835
Open Access | Times Cited: 7
Fruquintinib as new treatment option in metastatic colorectal cancer patients: is there an optimal sequence?
Erika Stucchi, Michela Bartolini, Marco Airoldi, et al.
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 4, pp. 371-382
Open Access | Times Cited: 7
Immunotherapy for Microsatellite-Stable Metastatic Colorectal Cancer: Can we close the Gap between Potential and Practice?
Marwa Abdel Hamid, Lorenz M. Pammer, Theresa Lentner, et al.
Current Oncology Reports (2024) Vol. 26, Iss. 10, pp. 1258-1270
Open Access | Times Cited: 7
From Crypts to Cancer: A Holistic Perspective on Colorectal Carcinogenesis and Therapeutic Strategies
Ehsan Gharib, Gilles A. Robichaud
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 17, pp. 9463-9463
Open Access | Times Cited: 7
The role of immunotherapy in microsatellites stable metastatic colorectal cancer: state of the art and future perspectives
Annalice Gandini, Silvia Puglisi, Chiara Pirrone, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 13
The characteristics of the tumor immune microenvironment in colorectal cancer with different MSI status and current therapeutic strategies
Qingzhe Wang, Min Yu, Shuang Zhang
Frontiers in Immunology (2025) Vol. 15
Open Access
CITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid tumours
J. Randolph Hecht, Jean‐Marie Michot, David J. Bajor, et al.
BJC Reports (2025) Vol. 3, Iss. 1
Open Access
CSCO guidelines for colorectal cancer version 2024: Updates and discussions.
Liubo Chen, Hanguang Hu, Ying Yuan, et al.
PubMed (2024) Vol. 36, Iss. 3, pp. 233-239
Closed Access | Times Cited: 4
The efficacy and safety of suvemcitug, envafolimab, and FOLFIRI in microsatellite-stable or mismatch repair–proficient colorectal cancer: preliminary results of a phase 2 study
Ying Liu, Jufeng Wang, Yong Fang, et al.
International Journal of Colorectal Disease (2025) Vol. 40, Iss. 1
Open Access
Tumor aggression-defense index–a novel indicator to predicts recurrence and survival in stage II-III colorectal cancer
Tong Wu, Lin Fang, Yuli Ruan, et al.
Journal of Translational Medicine (2025) Vol. 23, Iss. 1
Open Access
Chemotherapy boosts anti-angiogenic and anti-PD-1 combination therapy through activation of cCAS-STING pathway in colon cancer
Xiaofei Li, Yu-Wen Dong, Tingyu Wang, et al.
International Immunopharmacology (2025) Vol. 149, pp. 114212-114212
Closed Access
Efficacy and safety of fruquintinib combined with PD-1 inhibitors in the treatment of refractory metastatic colorectal cancer: a systematic review and meta-analysis
Linfeng Liu, Dengzhuo Chen, Liang Wen, et al.
Expert Review of Anticancer Therapy (2025)
Closed Access
Enhancing Colorectal Cancer Treatment Through VEGF/VEGFR Inhibitors and Immunotherapy
Jing Jiao, You Wu, Shaoxian Wu, et al.
Current Treatment Options in Oncology (2025)
Closed Access
Efficacy and safety of sintilimab plus bevacizumab and CAPOX as first-line treatment for patients with RAS-mutant, microsatellite stable, metastatic colorectal cancer
Yanrong Wang, Ru Jia, Haiyan Si, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
Immune Checkpoint Blockade Therapies for Colorectal Cancer: Current Strategies and Emerging Approaches
Kelly Pum, Christopher J. LaRocca, Paolo Goffredo, et al.
JCO oncology advances. (2025), Iss. 2
Closed Access
Page 1 - Next Page

Scroll to top